Brief: Zevra Therapeutics To Present Top-Line Data From The Phase 2 Clinical Trial Of Kp1077 For Idiopathic Hypersomnia At Sleep Europe 2024
24/09/2024 12:31
Sept 24 (Reuters) - Zevra Therapeutics Inc ZVRA.O :
* ZEVRA THERAPEUTICS TO PRESENT TOP-LINE DATA FROM THE PHASE
2
CLINICAL TRIAL OF KP1077 FOR IDIOPATHIC HYPERSOMNIA AT SLEEP
EUROPE 2024
Source text for Eikon: ID:nGNX4JvWGn
Further company coverage: ZVRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor